close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by GenSight Biologics S.A.

News headline image
The 15-20 National Hospital and GenSight Biologics Announce the Treatment of the First Patient in the GS010/LUMEVOQ® REVISE Study
From GenSight Biologics S.A.
Via Business Wire
News headline image
GenSight Biologics Announces the Results of its Extraordinary General Meeting of January 28, 2026
From GenSight Biologics S.A.
Via Business Wire
News headline image
GenSight Biologics Announces Regulatory Authorization for Early Access Treatment with GS010/LUMEVOQ® in Israel
From GenSight Biologics S.A.
Via Business Wire
News headline image
GenSight Biologics Announces the Granting of Compassionate Use Authorization (CUA/AAC) for GS010/LUMEVOQ® in France
From GenSight Biologics S.A.
Via Business Wire
News headline image
GenSight Biologics Postpones Release of 2025 Half-Year Financial Results
From GenSight Biologics S.A.
Via Business Wire
News headline image
GenSight Biologics Announces the Filing of its 2024 Universal Registration Document
From GenSight Biologics S.A.
Via Business Wire
News headline image
GenSight Biologics Reports Estimated Full-Year 2024 Consolidated Financial Results
From GenSight Biologics S.A.
Via Business Wire
News headline image
GenSight Biologics Announces Publication of 5-Year Outcomes for Patients Treated Unilaterally with LUMEVOQ® Gene Therapy
From GenSight Biologics S.A.
Via Business Wire
News headline image
GenSight Biologics Provides Update on Regulatory Discussions and Financial Situation
From GenSight Biologics S.A.
Via Business Wire
News headline image
GenSight Biologics Announces Submission of LUMEVOQ® Dossier to ANSM to Prepare for Restart of Early Access Program in France
From GenSight Biologics S.A.
Via Business Wire
News headline image
GenSight Biologics Announces Publication of Meta-Analyses Showing Better Outcomes for ND4-LHON Patients Treated with LUMEVOQ®
From GenSight Biologics S.A.
Via Business Wire
News headline image
GenSight Biologics Reports Cash Position as of September 30, 2024, and Provides Business Update
From GenSight Biologics S.A.
Via Business Wire
News headline image
GenSight Biologics Reports Interim Financial Results for the First Half of 2024, Provides Business Updates
From GenSight Biologics S.A.
Via Business Wire
News headline image
GenSight Biologics Reports Cash Position as of June 30, 2024, and Provides Business Update
From GenSight Biologics S.A.
Via Business Wire
News headline image
GenSight Biologics Renegotiates Financial Obligations and Provides Operational Updates
From GenSight Biologics S.A.
Via Business Wire
News headline image
GenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business Update
From GenSight Biologics S.A.
Via Business Wire
News headline image
GenSight Biologics Reports Full Year 2023 Consolidated Financial Results
From GenSight Biologics S.A.
Via Business Wire
News headline image
GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with LUMEVOQ® Gene Therapy at NANOS 2024
From GenSight Biologics S.A.
Via Business Wire
News headline image
GenSight Biologics Announces Update on Real-World Data from Early Access Programs of LUMEVOQ® Gene Therapy at NANOS 2024
From GenSight Biologics S.A.
Via Business Wire
News headline image
GenSight Biologics Announces Presentation of LUMEVOQ® Efficacy and Safety Data from Early Access Programs for ND4-LHON Patients at NANOS 2023
From GenSight Biologics S.A.
Via Business Wire
News headline image
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 3-Year Follow-Up of REFLECT Phase III Trial
From GenSight Biologics S.A.
Via Business Wire
News headline image
GenSight Biologics Announces Publication of LUMEVOQ® Safety Data over 5-Year Period in renowned Peer-Reviewed American Journal of Ophthalmology
From GenSight Biologics S.A.
Via Business Wire
News headline image
GenSight Biologics Announces Publication of a Study of the Impact of LHON Disease on the Lives of Patients and Relatives in Journal of Neuro-Ophthalmology
From GenSight Biologics S.A.
Via Business Wire
News headline image
GenSight Biologics Reports Clinically Meaningful Vision Improvement is Maintained 4 Years After One-time Treatment with LUMEVOQ® Gene Therapy
From GenSight Biologics S.A.
Via Business Wire
News headline image
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 2-Year Follow-Up of REFLECT Phase III Trial
From GenSight Biologics S.A.
Via Business Wire
News headline image
GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US
From GenSight Biologics S.A.
Via Business Wire
News headline image
GenSight Biologics Announces the Publication of a Review of Gene Therapy Trials for LHON in International Ophthalmology Clinics
From GenSight Biologics S.A.
Via Business Wire
News headline image
GenSight Biologics Announces Publication Analyzing Visual Parameters of ND4-LHON Subjects Before LUMEVOQ® Treatment in Phase III Trials
From GenSight Biologics S.A.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today